Tradestie Institutional Equity Comparison Engine
MTLS vs CGEN โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
CGEN Overall Edge
CGEN Captures Institutional Edge (3โ1 Pillars ยท 7โ3 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Compugen Ltd (CGEN) driven by superior Valuation, Growth & Margin, Options & Structure while MTLS counters with relative strength in Momentum & Technical. Fundamentally, MTLS trades at N/M Forward P/E with 3.4% operating margin (+2.1% YoY revenue) versus CGEN at 12.4x Forward P/E and 41.3% operating margin (+102.1% YoY). In options structure, MTLS sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro) against CGEN sits in BREAKDOWN (57th %ile IV; Dealer Gamma Walls on Pro).
Valuation Winner
CGEN
MTLS N/M vs CGEN 12.4x Fwd P/E
Growth & Margin Winner
CGEN
Op Margin 3.4% vs 41.3% ยท YoY +2.1% vs +102.1%
Momentum & Technical Winner
MTLS
1Y +4.5% vs +23.2% ยท 52W Pos 37% vs 33%
Options & Structure Winner
CGEN
UNCLASSIFIED (N/A IV) vs BREAKDOWN (57th %ile IV)
MTLS
NASDAQ
Materialise NV
Services-Prepackaged Software
$6.28
+1.13% 1D
Market Cap
$369.9M
1M Return
-22.52%
1Y Return
+4.49%
Forward P/E
N/M
Unified AI Score
53.5 / 100
HOLD
Tech 53.0
Fund 53.0
Flow 50.0
Mom 60.0
CGEN
NASDAQ
Compugen Ltd
Biological Products, (No Diagnostic Substances)
$2.02
-0.98% 1D
Market Cap
$198.9M
1M Return
+2.54%
1Y Return
+23.17%
Forward P/E
12.4x
Unified AI Score
47.1 / 100
HOLD
Tech 44.0
Fund 52.0
Flow 54.0
Mom 64.0
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
1Y Indexed Return:
MTLS +4.49%
CGEN +23.17%
Spread: +18.68 pp (CGEN Lead)
Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)
MTLS TTM Op. Margin: 3.4%
CGEN TTM Op. Margin: 41.3%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on MTLS vs CGEN. Trailing 12-month operating profitability (MTLS 3.4% vs CGEN 41.3%) and valuation multiples (MTLS N/M vs CGEN 12.4x Forward P/E) are benchmarked directly in Pillar 4 below.
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | MTLS | CGEN | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $369.9M | $198.9M | Larger Scale | MTLS |
| Trailing P/E Ratio Valuation | 25.0x | 5.4x | Lower Multiple | CGEN |
| Forward P/E Ratio Valuation | N/M | 12.4x | Lower Multiple | CGEN |
| Revenue Growth (YoY) Growth | +2.1% | +102.1% | Higher Growth | CGEN |
| Operating Margin (TTM) Profitability | 3.4% | 41.3% | Higher Margin | CGEN |
| Net Profit Margin Profitability | 4.6% | 47.9% | Higher Margin | CGEN |
| Return on Equity (ROE) Capital Efficiency | 5.0% | 57.2% | Higher ROE | CGEN |
| 52-Week Range Position Momentum | 37% ($5โ$9) | 33% ($1โ$3) | Stronger Trend | MTLS |
| Beta / 30D Volatility Risk Regime | 1.10ฮฒ ยท 88% Vol | 1.44ฮฒ ยท 62% Vol | Lower Realized Risk | CGEN |
| Unified Institutional Score Composite Signal | 53.5 / 100 (HOLD) | 47.1 / 100 (HOLD) | Higher Composite | MTLS |
Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor
Full MTLS vs CGEN Buy Guide
MTLS
UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
N/A
IV Regime
Unclassified
CGEN
BREAKDOWN
143d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
57th %ile
IV Regime
Balanced (25thโ60th %ile)
Pillar 6 90-Day Technical & R&D Innovation Disclosures
Corporate R&D & Foundry Tracker
Neither MTLS nor CGEN registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.